At ASH, positive news for Terns, Kura leukemia treatments

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events.

This is the online version of ASH in 30 Seconds, STAT’s report from the American Society of Hematology meeting. Sign up for the email version here. 

It rains in Florida. A lot. This ASH meeting started sunny and wonderful, but quickly turned rainy and miserable. It’s just another reason why ASH should camp itself permanently in San Diego each December.

Study suggests Terns leukemia drug could be successor to Novartis blockbuster

Adam Feuerstein/STAT

Terns Pharmaceuticals reported an update on its targeted leukemia drug that maintained and even boosted high molecular response rates in advanced-stage patients.